Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Lumens to Host the Women in Design Summit on March 28, 14-03-2023, 22:30

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference 14-01-2025, 13:00